ADAMTS13 and graft versus host disease: Our current study showed that the administration of exogenous ADAMTS13 in the initial days of bone marrow transplant (Day −2 and Day +3) was adequate to have a long‐lasting impact on reducing the severity of GVHD and GVHD‐related mortality.